| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg | |||
| Other Sizes |
| Targets |
Rac-PT2399 targets hypoxia-inducible factor 2alpha (HIF-2alpha), a transcription factor involved in cellular adaptation to low oxygen and a key driver of tumor progression. HIF-2alpha is a therapeutic target in oncology, particularly in renal cell carcinoma and other cancers where HIF-2alpha is dysregulated. Rac-PT2399 inhibits HIF-2alpha with an IC₅0 of 0.01 microM.
|
|---|---|
| ln Vitro |
Rac-PT2399 demonstrates potent in vitro inhibition of HIF-2alpha with an IC₅0 of 0.01 microM. As a racemic mixture of PT2399, it serves as both a therapeutic lead and a research tool in oncology. The compound shows specificity for HIF-2alpha inhibition.
|
| ln Vivo |
In vivo, Rac-PT2399 is used as a research tool to study HIF-2alpha function and its role in tumor progression. HIF-2alpha inhibitors are being developed as cancer therapeutics, particularly for renal cell carcinoma. Further in vivo studies in appropriate tumor models would be required to fully characterize its therapeutic potential.
|
| Enzyme Assay |
In vitro binding assays for Rac-PT2399 typically employ purified HIF-2alpha protein or HIF-2alpha-PAS domain constructs. Binding affinity is assessed using surface plasmon resonance (SPR), isothermal titration calorimetry (ITC), or fluorescence polarization. Inhibition of HIF-2alpha transcriptional activity is assessed using reporter gene assays in cells expressing HIF-2alpha.
|
| Cell Assay |
In vitro cellular assays for Rac-PT2399 involve treating HIF-2alpha-dependent cancer cell lines (e.g., 786-O renal cell carcinoma cells) with varying concentrations of the compound (typically 0.001-100 microM range) for 24-72 hours. Readouts include assessment of HIF-2alpha target gene expression (e.g., VEGF, GLUT1) by qPCR, cell viability, and evaluation of downstream signaling pathways.
|
| Animal Protocol |
In vivo animal studies for Rac-PT2399 would typically employ xenograft mouse models bearing HIF-2alpha-dependent tumors (e.g., renal cell carcinoma). Tumor-bearing mice would be administered Rac-PT2399 via appropriate routes at various doses. Tumor growth inhibition would be monitored over 2-4 weeks. Endpoints would include tumor volume, body weight, and pharmacodynamic biomarkers of HIF-2alpha inhibition.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Rac-PT2399 are characteristic of small molecule HIF-2alpha inhibitors. With a molecular weight of 419.32, the compound is a small molecule. PK parameters including half-life, Cmax, Tmax, and AUC would be determined via LC-MS/MS analysis following administration in appropriate animal models.
|
| Toxicity/Toxicokinetics |
Rac-PT2399 is a research-grade compound for laboratory use only. As with all research chemicals, standard safety precautions should be observed during handling including appropriate PPE and work in a fume hood. The compound is not intended for human therapeutic use. Comprehensive toxicology data is not publicly available.
|
| References | |
| Additional Infomation |
Rac-PT2399 (CAS# 1672662-07-5) is a potent and specific HIF-2alpha inhibitor (IC₅0 = 0.01 microM). It is the racemic mixture of PT2399 and serves as a research tool in oncology. The compound is not approved for clinical use and is for research purposes only.
|
| Molecular Formula |
C17H10F5NO4S
|
|---|---|
| Molecular Weight |
419.322620868683
|
| Exact Mass |
419.025
|
| CAS # |
1672662-07-5
|
| Related CAS # |
PT2399;1672662-14-4
|
| PubChem CID |
117947087
|
| Appearance |
White to off-white solid powder
|
| LogP |
3.3
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
10
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
28
|
| Complexity |
734
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(C(F)F)(C1=CC=C(C2CC(C(C=21)O)(F)F)OC1C=C(C=C(C#N)C=1)F)(=O)=O
|
| InChi Key |
MXUSGDMIHGLCNC-HNNXBMFYSA-N
|
| InChi Code |
InChI=1S/C17H10F5NO4S/c18-9-3-8(7-23)4-10(5-9)27-12-1-2-13(28(25,26)16(19)20)14-11(12)6-17(21,22)15(14)24/h1-5,15-16,24H,6H2/t15-/m0/s1
|
| Chemical Name |
3-[(1S)-7-(Difluoromethylsulfonyl)-2,2-difluoro-1-hydroxy-indan-4-yl]oxy-5-fluoro-benzonitrile
|
| Synonyms |
PT2399 PT-2399 PT 2399
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~120 mg/mL (~286.18 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 3 mg/mL (7.15 mM) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 3 mg/mL (7.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 30.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.3848 mL | 11.9241 mL | 23.8481 mL | |
| 5 mM | 0.4770 mL | 2.3848 mL | 4.7696 mL | |
| 10 mM | 0.2385 mL | 1.1924 mL | 2.3848 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
